Alzamend Neuro Inc Down 2.97% To $0.98 After Earnings Miss

Alzamend Neuro Inc (ALZN) said after close Monday that it lost $0.38 per share in quarter three 2024. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $0.9 per share on revenue of $0.00.

The stock is down 2.97% to $0.98 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Hold on the stock prior to the report.

Trading in the five days leading up to the report earned Alzamend Neuro Inc a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 4. Meanwhile, the average Wall Street analyst rated the stock a Hold.

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.